Navigation Links
Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
Date:10/29/2010

ortfolio will continue to drive total revenue growth; however, the rate of growth will reduce in the fourth quarter as we will not benefit from the one off adjustment to ADDERALL XR Medicaid rebates and high level of royalties experienced in the same period last year. The consolidation of Movetis will also mean that combined R&D and SG&A spend for 2010 is likely to grow at marginally above 10% year on year.

Shire has made significant progress in 2010. Growth across our core portfolio, particularly the accelerated growth of our HGT business, has enabled us to increase our expectations of earnings while also making targeted investments in our pipeline and international structure. We expect to see solid earnings growth in 2011, but at a rate that reflects the pull ahead into 2010 of some of HGT's growth potential.

PRODUCT LAUNCHES

Subject to obtaining the relevant regulatory/governmental approvals, future product launches in the next 12 months include:

- VYVANSE/VENVANSE for the treatment of Attention Deficit Hyperactivity Disorder ("ADHD") in adolescents in the US and children in Brazil; - INTUNIV as adjunctive treatment to long acting oral stimulants for the treatment of ADHD in children and adolescents in the US; - EQUASYM(R) for the treatment of ADHD in certain European Union ("EU") countries; - RESOLOR(R) in certain EU countries, for the symptomatic treatment of chronic constipation in women for whom laxatives fail to provide adequate relief; - LIALDA/MEZAVANT for the maintenance of remission of ulcerative colitis in the US and for the treatment of ulcerative colitis in certain countries; - VPRIV for the treatment of type 1 Gaucher disease in certain European and Latin American countries; and - FIRAZYR(R) for the symptomatic treatment of acute attacks of hereditary angioedema ("HAE") in the US and certain European and Latin American countries. PRODUCT AND PIPELINE DEVELOPMENTS Products PENTASA(R) - for the treatment of Ulcer
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
2. Reportlinker Adds Shire plc: PharmaVitae Profile
3. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
4. Shire plc - Statement re ProAmatine
5. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
6. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
7. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
8. Shire plc Appoints Two New Board Directors
9. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
10. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
11. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 ... Market Research "Electrodes for Medical Devices Market (Diagnostic Electrodes ... Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other ... and Forecast, 2013 - 2019," the global electrodes market ... in 2012 and is estimated to reach a market ...
(Date:7/31/2014)... SAN DIEGO, July 31, 2014 ... a leading company using proprietary taste science technologies ... for the food, beverage, and ingredient supply industries, ... 2014.  The Company ended the second quarter with ... "During the past quarter Senomyx ...
(Date:7/31/2014)... Francisco, Calif. (PRWEB) July 31, 2014 ... newly diagnosed patients with an overview of the disease ... management of drug side effects, as well as updates ... “We’re grateful to Dr. Sandy Srinivas for organizing this ... survivor of kidney cancer. “Sandy and her colleagues have ...
(Date:7/31/2014)... Although RNA-Sequencing is a relatively new ... appearing around 2008, RNA-Sequencing has rapidly evolved to ... the last several years, assays have improved to ... input amounts, process degraded RNA, and perform well ... bioinformatics side, there have been improvements in references, ...
Breaking Biology Technology:Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 2Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 5Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks 2
... had the opportunity to discuss the role of technology ... based services - internally and externally for constituents. The ... investment funding and health insurance. He also shared his ... to limit unsolicited e-mail. , , WTN: ...
... with two research grants coming over the transom almost at ... non-profit subsidiary of the Wisconsin Alumni Research Foundation (WARF), ... of human embryonic stem cells. , ,The grant and ... Embryonic Stem Cell Research come from the National Institute ...
... at Menasha Advantage, a subsidiary of Neenahs Menasha Corp., ... Skunkworks. There, a better cardboard box is being born. ... Advantage is building a system to track shipments from ... Internet-based system will save time, money and headaches for ...
Cached Biology Technology:WTN Interview with Governor Doyle 2WTN Interview with Governor Doyle 3WTN Interview with Governor Doyle 4WTN Interview with Governor Doyle 5WTN Interview with Governor Doyle 6Double header for research dollars from Washington 2E-Commerce Skunkworks in Menhasa 2E-Commerce Skunkworks in Menhasa 3
(Date:7/31/2014)... known that biomass burning burning forests to ... , slash-and-burn agriculture and wildfires figures into ... until the release of a new study by ... Z. Jacobson, the degree of that contribution had ... in a paper published July 30 in the ...
(Date:7/31/2014)... of scientists from Spain, France, and the U.S. ... is the oldest definitive member of the tribe ... The discovery and description were made possible through ... imaging technique, which allows the detailed study of ... species is described in the journal Annals ...
(Date:7/31/2014)... Since Alexandre Edmond Becquerel first discovered the photovoltaic effect ... harness the power of sunlight for its own purposes. ... 2014 issue of the FASEB Journal ... exploiting the power of sunlight by focusing on a ... conserved throughout evolution. This conservationor persistence over time and ...
Breaking Biology News(10 mins):Stanford professor finds that wildfires and other burns play bigger role in climate change 2Stanford professor finds that wildfires and other burns play bigger role in climate change 3Stanford professor finds that wildfires and other burns play bigger role in climate change 4Scientists shine bright new light on how living things capture energy from the sun 2
... bypass, the most common type of bariatric surgery in ... therapy for morbid obesity. Patients who undergo this procedure, ... pouch and connected to the middle of the small ... reasons behind this surgery,s success have been unclear. Shedding ...
... -- July 26, 2011 - The Guy Harvey Ocean ... Neil Hammerschlag, Ph.D., director of the RJ Dunlap Marine ... research "Assessing the Cascading Ecosystem Impacts of Marine Apex ... of declining populations of tunas, billfish and sharks on ...
... to decide what to eat for dinner. Should it be ... entirely and just get some Rocky Road? Making that ... according to researchers from the California Institute of Technology (Caltech), ... of attention toward the healthy side of life. And that ...
Cached Biology News:Study suggests weight loss from gastric bypass may be partly due to dietary fat aversion 2Study suggests weight loss from gastric bypass may be partly due to dietary fat aversion 3Think healthy, eat healthy: Caltech scientists show link between attention and self-control 2Think healthy, eat healthy: Caltech scientists show link between attention and self-control 3Think healthy, eat healthy: Caltech scientists show link between attention and self-control 4